Beta-Glucan (β-glucan)
Beta-glucan is a family of soluble polysaccharides that occur in two biochemically and regulatorily distinct classes. Beta-(1-3,1-4)-D-glucan from the cell walls of oats and barley is a soluble viscous fibre with UK-authorised health claims for blood cholesterol maintenance and post-meal blood glucose response — at daily intakes of at least 3 g (cholesterol) and 4 g per 30 g available carbohydrate (post-meal glucose). A separate UK Article 14 reduction-of-disease-risk claim permits "oat beta-glucan has been shown to lower/reduce blood cholesterol" provided 3 g daily is delivered. Beta-(1-3,1-6)-D-glucan from medicinal mushrooms (shiitake, maitake, reishi, chaga, lions-mane, cordyceps, tremella) and from baker's yeast occupies a different regulatory category — no UK or EU food-supplement-tier health claim is authorised for mushroom or yeast beta-glucans, despite a substantial cell-biology literature on innate-immune signalling via the Dectin-1 receptor. UK supplement marketing must respect the distinction: cholesterol-maintenance language is authorised only for oat / barley beta-glucan at the right dose; "immune support" language for mushroom or yeast beta-glucan is not authorised.
Camden Medicals editorial · Last reviewed 6 May 2026 · Next review May 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Other
- Typical daily dose
- Cholesterol claim threshold: ≥3 g/day oat or barley beta-glucan (Article 13.1 and Article 14). Post-meal glucose claim threshold: ≥4 g beta-glucan per 30 g available carbohydrate per meal. Trial ranges in cholesterol meta-analyses (Whitehead 2014; Ho 2016) spanned 1-10 g/day with effect sizes increasing modestly above 3 g/day. Mushroom and yeast beta-glucan trial range is roughly 100-500 mg/day standardised extract with no UK threshold (because no authorised claim).
- Top use evidence
- Strong
On this page
What it is
Beta-glucan is a family of soluble polysaccharide molecules made up of glucose units linked by β-glycosidic bonds. The position and orientation of those bonds determines both the molecule's physical behaviour in the gut and its biological activity. Two classes occur in human nutrition:
β-(1-3,1-4)-D-glucan — from cereal grains, principally oats (Avena sativa) and barley (Hordeum vulgare). The 1-4 linkages give the molecule a long, semi-rigid chain that becomes highly viscous in water. In the small intestine this viscous gel slows gastric emptying, traps bile acids, and slows glucose absorption — producing the lowered LDL-cholesterol and reduced post-meal glucose effects measured in human trials. Oat bran (the dehulled outer layer of the oat groat) typically contains 5-7% beta-glucan; whole oats contain 3-7%; barley contains around 5%. Concentrated oat-beta-glucan extracts (e.g. PromOat®, OatWell®) are standardised to higher beta-glucan content for use in functional foods and supplements.
β-(1-3,1-6)-D-glucan — from the cell walls of fungi (medicinal mushrooms — Lentinula edodes / Hericium erinaceus / Ganoderma lucidum / Grifola frondosa / Inonotus obliquus / Trametes versicolor / Cordyceps militaris / Pleurotus ostreatus / Tremella fuciformis) and from baker's yeast (Saccharomyces cerevisiae). The 1-6 branching gives the molecule a different three-dimensional shape — short side-chains projecting off a backbone — that fits into the binding cleft of the Dectin-1 receptor on innate immune cells (macrophages, neutrophils, dendritic cells), triggering downstream signalling. The 1-6 form is NOT a viscous fibre and does not produce the cholesterol-lowering or post-meal-glucose effects of the cereal beta-glucan.
The two share a name and a chemical family but are different molecules with different physiological roles and different regulatory positions. Camden's ingredient encyclopaedia carries entries for the major medicinal-mushroom sources (shiitake, maitake, reishi, chaga, cordyceps, lions-mane, tremella) — each links back to this entry as the canonical molecular and regulatory reference.
At a glance
- Two biochemically distinct classes: β-(1-3,1-4)-D-glucan from oats and barley (soluble viscous fibre — cholesterol and post-meal glucose claims authorised); β-(1-3,1-6)-D-glucan from mushrooms and yeast (innate-immune signalling molecule — no authorised health claim).
- UK Article 13.1 authorised: "Regular consumption of beta-glucans contributes to the maintenance of normal blood cholesterol levels" — at ≥3 g/day intake from oats / barley.
- UK Article 14 reduction-of-disease-risk claim authorised (Reg 1160/2011): "Oat beta-glucan has been shown to lower/reduce blood cholesterol" — at ≥3 g/day intake. Use of this claim requires the labelling caveat that high cholesterol is a risk factor in coronary heart disease.
- UK Article 13.1 authorised for post-meal glucose: "Consumption of beta-glucans from oats or barley as part of a meal contributes to the reduction of the blood glucose rise after that meal" — at ≥4 g/30 g available carbohydrate per meal.
- Mushroom and yeast β-(1-3,1-6) glucans (Lentinex® from shiitake, Wellmune® WGP from yeast, similar) — no authorised UK food-supplement health claim. EFSA Article 13.5 evaluations are on hold or have not been approved. UK marketing must stay descriptive — no "immune support" or "natural defence" wording.
- Quality marker for ANY beta-glucan supplement: source declared (oat / barley / mushroom / yeast) AND beta-glucan percentage of the extract declared. Generic "mushroom beta-glucan" without species identification or content declaration tells you nothing about the product.
What people use it for
Adults aiming to lower borderline-elevated LDL cholesterol via dietary changes
Daily intake of ≥3 g oat or barley beta-glucan from oats, oat bran, oat-based breakfast cereals, or oat-beta-glucan supplements is a UK-authorised maintenance-of-blood-cholesterol intervention. The Article 14 reduction-of-disease-risk claim adds the framing that lowered cholesterol may reduce coronary heart disease risk. The effect is modest (~5-10% LDL reduction in trial pools) and the evidence is for sustained daily intake, not occasional servings. UK NICE NG238 is the cardiovascular disease primary prevention pathway — speak to a GP for full lipid management. [6,7]
Some evidenceStrongAdults with type-2 diabetes managing post-meal blood-glucose excursions
Including oats / barley / oat-beta-glucan in carbohydrate-containing meals at ≥4 g beta-glucan per 30 g available carbohydrate has a UK-authorised post-meal-glucose-response claim. This is a meal-by-meal effect — not a chronic glycaemic-control effect. Dietary changes for type-2 diabetes should be agreed with the diabetes team; UK NICE NG28 is the management pathway. [4]
Some evidenceStrongAdults considering "mushroom beta-glucan" or "yeast beta-glucan" supplements for general immune support
There is no UK-authorised health claim for mushroom or yeast beta-glucan for immune function or any other indication. Marketing must therefore stay descriptive (e.g. "traditionally consumed in East Asian cuisine"). Small RCTs of specific proprietary preparations (Lentinex® shiitake-derived, Wellmune® WGP yeast-derived, AHCC® shiitake mycelium-derived) have reported modest immunological-biomarker changes but no hard clinical endpoints in healthy adults. [8]
Some evidenceLimitedAdults considering beta-glucan as a cancer remedy or immunotherapy adjunct
Beta-glucan is not a UK-recognised pathway for cancer or as a chemotherapy adjunct. Lentinan (an isolated β-(1-3,1-6) glucan from shiitake) is licensed as an intravenous chemotherapy adjunct in Japan but is NOT a UK food supplement and is NOT the same therapeutic preparation as oral mushroom-beta-glucan supplements. UK NICE pathways for cancer treatment apply. Talk to your oncology team before starting any supplement. [9]
Popular, not provenInsufficient
How it works
Cereal β-(1-3,1-4) glucan — bile-acid sequestration mechanism for cholesterol effect. In the small intestine the soluble viscous fibre forms a gel that physically traps bile acids, preventing their reabsorption in the terminal ileum (where roughly 95% of bile acids are normally recycled via the enterohepatic circulation). The trapped bile acids are excreted in faeces. The liver compensates by drawing more cholesterol from circulation to synthesise replacement bile acids, with consequent reduction in serum LDL cholesterol. The effect requires daily exposure (≥3 g/day for cholesterol effect; ≥4 g/30 g carb for post-meal glucose effect) — a few servings per week is not enough.
Cereal β-(1-3,1-4) glucan — slowed-absorption mechanism for post-meal glucose. The viscous gel slows gastric emptying and slows glucose diffusion across the unstirred water layer at the intestinal brush border. The result is a lower and broader post-meal glucose peak. The effect is meal-by-meal — not a chronic effect carried between meals.
Mushroom / yeast β-(1-3,1-6) glucan — Dectin-1-mediated innate immune signalling. The 1,6-branched structure binds the C-type lectin receptor Dectin-1 on macrophages, neutrophils, and dendritic cells, plus complement receptor 3 (CR3) and TLR2 in some preparations. Receptor binding triggers Syk-mediated and CARD9-dependent intracellular signalling, with downstream cytokine release and modulation of phagocytic activity. Translation from this in-vitro and animal-model mechanism to clinical outcomes in healthy adults at oral food-supplement doses is not established. Most published clinical work on mushroom or yeast beta-glucan in healthy adults reports modest changes in immunological biomarkers (cytokine levels, NK-cell activity, salivary IgA) rather than hard clinical endpoints. The Dectin-1 mechanism is also dose-dependent and form-dependent — particulate β-glucan (e.g. Wellmune WGP yeast preparation) and soluble β-glucan can have different signalling profiles.
Common myths
Myth""All beta-glucans are the same — mushroom and oat are interchangeable.""
RealityThey are not. Oat and barley β-(1-3,1-4) glucan is a soluble viscous fibre that lowers cholesterol via bile-acid sequestration. Mushroom and yeast β-(1-3,1-6) glucan is an innate-immune signalling molecule that binds Dectin-1 on macrophages. The molecules have different shapes, different physiological behaviour, and different regulatory positions — only oat and barley beta-glucan have UK-authorised health claims. [7]
Myth""Mushroom beta-glucan boosts your immune system.""
RealityUK marketing for mushroom beta-glucan cannot make immune-system claims because EFSA's evaluation of mushroom beta-glucan immune claims is on hold or has not been approved. The mechanism (Dectin-1 binding) is real at cell-biology level; clinical translation in healthy adults at oral supplement doses is modest immunological- biomarker change rather than hard infection-rate reduction. The word "boost" is also editorially loaded — the immune system is not a thermostat that beta-glucan turns up. [8]
Myth""A 500 mg mushroom beta-glucan capsule is the same as a Lentinan injection.""
RealityIt is not. Lentinan is an isolated, purified, high-molecular-weight β-(1-3,1-6) glucan administered intravenously as a Japanese chemotherapy adjunct, with hospital-pharmacy oversight. Oral mushroom beta-glucan supplements deliver a heterogeneous mix of polysaccharides at low oral bioavailability. The two are different therapeutic preparations and the trial evidence for one does not transfer to the other.
Myth""Higher percentage beta-glucan content = better mushroom supplement.""
RealityHigher declared beta-glucan content from a verified extraction method (typically hot-water extraction) is genuinely a better quality marker than no declaration at all. But "90% beta-glucan" on a label is not necessarily 90% β-(1-3,1-6) glucan from the named mushroom — it could be supplemented with cheaper β-(1-3,1-4) starch-derived material that registers as beta-glucan on the routine assay. Look for the assay method (Megazyme β-glucan kit, with disclosure that α-glucan content is also measured to exclude starch-based adulteration) and the source organism declared.
Myth""Eating oats once a week lowers my cholesterol.""
RealityThe UK-authorised oat-beta-glucan cholesterol claim requires ≥3 g/day, sustained. A single weekly serving does not match the trial conditions and is unlikely to produce the measured effect. Daily oat porridge (40-50 g rolled oats provides ~1.5-2.5 g beta-glucan) gets close to the threshold; daily oat bran or an oat-beta-glucan-fortified product is the easier route to ≥3 g/day. [7]
Common online questions
Synthesised from the questions UK shoppers most often ask online about Beta-Glucan (β-glucan). Each answer is editorial and links to its evidence in the Sources list below.
How much beta-glucan do I get from a bowl of porridge?
Roughly 1.5-2.5 g from 40-50 g of rolled oats, depending on the oat variety. Oat bran is more concentrated — about 4-5 g beta-glucan per 50 g serving. The UK-authorised cholesterol claim threshold is ≥3 g/day, so two bowls of standard porridge, one bowl of oat-bran-based porridge, or one porridge plus an oat-beta-glucan-fortified product gets you over the threshold. [7]
Can I take oat beta-glucan and a statin together?
Yes — they are not contraindicated together. Oat beta-glucan works on bile-acid recycling in the gut and statins work on cholesterol synthesis in the liver; the mechanisms are complementary. UK NICE NG238 cardiovascular pathways position dietary fibre alongside lipid-lowering medication, not in opposition. Talk to the prescribing GP if you want to confirm. [6]
Does mushroom beta-glucan really do anything for immunity?
At cell-biology level the Dectin-1 binding mechanism is real and well-described. At clinical level, small RCTs of specific proprietary preparations (Wellmune WGP yeast beta-glucan, Lentinex shiitake beta-glucan) have reported modest changes in immunological biomarkers but not hard clinical endpoints in healthy adults. UK marketing cannot make immune claims for mushroom beta-glucan because the EFSA evaluation is on hold. The honest position: there is a plausible mechanism, modest biomarker evidence, and no authorised claim — what each of those three says depends on what you want from a supplement. [8]
My supplement says "polysaccharide complex" not "beta-glucan" — same thing?
Not necessarily. "Polysaccharide complex" is a vaguer term that can include alpha-glucans (starch and starch-derived material), beta-glucans, chitin, and other cell-wall constituents. If beta-glucan is the active you want, look for explicit beta-glucan percentage declared with an assay method (Megazyme β-glucan kit is the industry standard) and the source organism named.
Are oat beta-glucan and barley beta-glucan interchangeable?
For UK-authorised health claims, yes — both are covered by the Article 13.1 cholesterol-maintenance and post-meal-glucose claims, and both reach the ≥3 g/day cholesterol threshold from regular dietary inclusion. The Article 14 disease-risk-reduction claim text is specifically for oat beta-glucan; barley beta-glucan does not carry the disease-risk-reduction claim wording but does carry the maintenance claim. [7]
⚖️ The official position
What may lawfully be claimed about Beta-Glucan (β-glucan) in Great Britain. This is a regulatory position, not an evidence grade.
A health claim is authorised in Great Britain.
“Beta-glucans contribute to the maintenance of normal blood cholesterol levels”
“Consumption of beta-glucans from oats or barley as part of a meal contributes to the reduction of the blood glucose rise after that meal”
This claim is authorised for use in Great Britain under the GB Nutrition and Health Claims regulation. A product may carry it when it provides at least 15% of the UK NRV per recommended daily portion.
Authorised UK health claims
Verbatim from the GB Nutrition and Health Claims Register (Reg 432/2012 as assimilated in GB). A product can carry these claims when it provides at least 15% of the UK NRV per recommended daily portion.
2 authorised claims — show / hide
- "Beta-glucans contribute to the maintenance of normal blood cholesterol levels"
- "Consumption of beta-glucans from oats or barley as part of a meal contributes to the reduction of the blood glucose rise after that meal"
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Cholesterol maintenance / reduction — oat and barley beta-glucan
StrongEvidencestrongEFSA Panel on Dietetic Products, Nutrition and Allergies issued positive scientific opinions on oat beta-glucan and cholesterol maintenance (2010, EFSA Journal 1254) and on the reduction-of- disease-risk claim under Article 14 (2010). The intake threshold is 3 g/day. Multiple RCTs and meta-analyses (Whitehead 2014; Ho 2016) have confirmed a modest LDL-cholesterol reduction of roughly 5-10% with sustained ≥3 g/day intake. UK NICE NG238 positions dietary fibre as part of cardiovascular primary prevention. The effect requires daily intake — occasional servings do not produce the trial-comparable effect. [7,6]
Post-meal blood-glucose response — oat and barley beta-glucan
StrongEvidencestrongEFSA issued a positive scientific opinion on the post-meal blood glucose claim for oat and barley beta-glucan (2011) at an intake of ≥4 g beta-glucan per 30 g available carbohydrate per meal. The mechanism (slowed gastric emptying, slowed brush-border glucose diffusion) is well-characterised. The effect is meal-by- meal; chronic glycaemic-control benefit (e.g. HbA1c reduction) is more modest and depends on overall dietary pattern. [10]
Immune function — mushroom and yeast beta-glucan
LimitedEvidencelimitedMultiple small RCTs of specific proprietary preparations (Wellmune® WGP yeast β-(1-3,1-6) glucan, Lentinex® shiitake-derived beta-glucan, AHCC® shiitake mycelium preparation) have reported modest immunological-biomarker changes (NK-cell activity, salivary IgA, cytokine levels, upper-respiratory symptom scores) at oral doses around 250-500 mg/day for 4-12 weeks. Hard clinical endpoints (rate of medically-confirmed infection, hospitalisation, mortality) are not established. EFSA Article 13.5 evaluations of immune-function claims for yeast and mushroom beta-glucan applications have not been approved or remain on hold. [8]
Cancer adjunct — oral mushroom beta-glucan supplements
InsufficientEvidenceinsufficientOral mushroom beta-glucan supplementation is not a UK-recognised cancer pathway. Lentinan (isolated β-(1-3,1-6) glucan from shiitake) is licensed as an INTRAVENOUS chemotherapy adjunct in Japan for advanced gastric cancer — this is not the same therapeutic preparation as oral supplements and is not licensed in the UK. Marketing oral mushroom beta-glucan as a cancer intervention is outside UK rules. UK NICE pathways for cancer treatment apply. [9]
Safety
Beta-glucan from oats, barley, mushrooms, and yeast is well-tolerated across normal dietary and supplement intakes for healthy adults. The most common side effects are bloating and altered bowel pattern at high intakes. People with documented oat / barley / mushroom / yeast allergy, with coeliac disease (for non-gluten-free oat sources), or on immunosuppressant medication should choose source and dose carefully.
Talk to your pharmacist or GP first if you:
- You have coeliac disease or non-coeliac gluten sensitivity — only certified gluten-free oat products are appropriate.
- You have a documented mushroom or yeast allergy.
- You take an immunosuppressant medication (transplant or autoimmune disease) — mushroom or yeast beta-glucan has theoretical Dectin-1-mediated immune-modulation effects; talk to your prescriber.
- You take a lipid-lowering medication and want to add oat beta-glucan — the mechanisms are complementary, but it is reasonable to mention to your GP.
- You are managing type-2 diabetes — oat / barley beta-glucan is a UK-recognised post-meal-glucose option but should be discussed with the diabetes team.
Common side effects: Gas, bloating, altered bowel pattern at high intakes. Allergic reaction in people with mushroom, yeast, oat, or barley allergy.
Pregnancy and breastfeeding
Dietary-tier oat and barley beta-glucan from food sources is safe in pregnancy. Mushroom or yeast beta-glucan supplements have limited pregnancy safety data — food-tier consumption of mushrooms is fine; concentrated supplement extracts should be discussed with a midwife or GP.
As pregnancy.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Documented oat, barley, mushroom, or yeast hypersensitivity (depending on source).
- Coeliac disease — for oat sources, only certified gluten-free preparations are appropriate.
Drug interactions
- Oral medications taken at the same time as a high-dose viscous-fibre serving — the gel can slow absorption of co-administered medication. Stagger dosing by ≥1-2 hours from a fibre-rich meal where possible.
- Immunosuppressant medication (ciclosporin, tacrolimus, biologic DMARDs) — theoretical mechanism-level interaction with mushroom or yeast β-(1-3,1-6) glucan via Dectin-1 / CR3 signalling. Disclose use to the prescribing team.
- Lipid-lowering medication — pharmacodynamic interaction with oat / barley beta-glucan is complementary, not antagonistic; not a contraindication but worth disclosing to the GP managing the lipid profile.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- GI bloating, gas, altered bowel pattern at intakes substantially above the 3 g/day cholesterol-claim threshold.
- Oat-allergic individuals: typical food-allergy symptoms (urticaria, GI upset, in rare cases anaphylaxis).
Rare side effects
- Mushroom or yeast hypersensitivity reactions for the β-(1-3,1-6) preparations.
- Theoretical Dectin-1-mediated immune modulation in people on immunosuppressants — reported case-by-case in transplant and autoimmune disease literature.
How to take it
- Typical supplemental range
- Cholesterol claim threshold: ≥3 g/day oat or barley beta-glucan (Article 13.1 and Article 14). Post-meal glucose claim threshold: ≥4 g beta-glucan per 30 g available carbohydrate per meal. Trial ranges in cholesterol meta-analyses (Whitehead 2014; Ho 2016) spanned 1-10 g/day with effect sizes increasing modestly above 3 g/day. Mushroom and yeast beta-glucan trial range is roughly 100-500 mg/day standardised extract with no UK threshold (because no authorised claim).
- Timing
- For cholesterol effect: any time of day, as long as daily intake is sustained. For post-meal-glucose effect: must be taken WITH the carbohydrate-containing meal — adding oat-beta-glucan to a separate snack does not lower the next meal's glucose response.
How to spot quality
Look for
- Source organism declared: "oat (Avena sativa)" / "barley (Hordeum vulgare)" / "shiitake (Lentinula edodes)" / "baker's yeast (Saccharomyces cerevisiae)" — the regulatory class follows from the source.
- Beta-glucan percentage declared on the label, with assay method (Megazyme β-glucan kit is the industry standard).
- For oat / barley products: grams of beta-glucan per serving stated, allowing easy sum to the ≥3 g/day cholesterol threshold or ≥4 g/30 g carb post-meal threshold.
- For mushroom products: hot-water extraction declared (the standard route for high β-(1-3,1-6) yield) and α-glucan content also measured (to exclude starch-based filler that registers as beta-glucan on naive assays).
- Branded standardised material (PromOat®, OatWell®, Lentinex®, Wellmune® WGP, AHCC®) for trial-matched product.
- GMP-certified manufacture.
Red flags
- Generic "polysaccharide complex" / "mushroom blend" without beta-glucan content declared.
- Mushroom beta-glucan products marketed for "immune boost" / "natural defence" — outside UK rules; EFSA claims on hold.
- Mushroom beta-glucan products marketed as cancer remedies, chemotherapy adjuncts, or "natural killer cell boosters" — outside UK rules and outside trial-evidence boundaries.
- Oat beta-glucan products at less than 0.75 g per serving — the user would need an unrealistic number of servings per day to reach the 3 g threshold.
- Cancer-treatment language for ANY beta-glucan source — the UK regulatory position is unambiguous.
- No assay method declared — beta-glucan content is method-sensitive and a number without a method behind it is uninformative.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Flaxseed (Linum usitatissimum) — whole seed, oil, and lignans
Moderate evidenceTwo complementary soluble fibres in cardiovascular-prevention dietary patterns — viscous (oat beta-glucan) plus mucilaginous (flaxseed) gives broader bile-acid sequestration coverage.
Oat / barley β-(1-3,1-4) glucan is a long-chain viscous polysaccharide that gels in the upper small intestine and traps bile acids before terminal-ileum reabsorption. Flaxseed mucilage is a chemically distinct mixed acidic and neutral polysaccharide with shorter chain length and a different gel-formation profile — it slows transit slightly later in the intestine and adds bulk through colonic fermentation as well.
The two are not mutually exclusive — combined daily intake (≥3 g oat beta-glucan + 1-2 tbsp ground flaxseed) gives broader fibre-fraction coverage than either alone, and the two are routinely combined in cardiovascular-prevention dietary advice (Mediterranean / DASH / Portfolio Diet patterns). UK NICE NG238 recommends 30 g/day total fibre intake; oat beta-glucan plus flaxseed is one well-evidenced route.
Ground flaxseed also delivers ALA omega-3 (~2 g per tbsp) and lignans — separate cardiovascular axes that this combination naturally captures.
Evidence: Portfolio Diet trials (Jenkins et al.) combine oat-beta-glucan, psyllium, plant sterols, soy protein, and almonds with consistent LDL-cholesterol reductions of 15-30%. UK NICE NG238 cardiovascular pathway includes both. [6]
Doses studied: ≥3 g/day oat beta-glucan plus 1-2 tablespoons (12-24 g) ground flaxseed daily. The combination is dietary, not packaged-supplement; functional-food versions exist (oat-flaxseed cereal blends).
Vitamin C
Limited evidenceCommon-cold-symptom-cluster pairing — yeast or mushroom β-(1-3,1-6) glucan and vitamin C are routinely co-formulated in winter immune supplements. Vitamin C carries the authorised UK immune claim; the beta-glucan does not.
Vitamin C is required for normal immune-cell function and carries the UK Article 13.1 authorised claim "Vitamin C contributes to the normal function of the immune system" at intakes above the 12 mg NRV trigger. Beta-glucan from yeast or mushrooms binds Dectin-1 on macrophages and innate immune cells with documented downstream cytokine modulation in cell-biology and small-RCT settings.
The pairing is not synergistic in any well-trialled sense — the two work on different parts of the immune system and there is no published RCT specifically testing the combination on hard clinical endpoints (medically-confirmed infection, hospitalisation). What the combination does deliver is a regulatory split: the supplement carries an authorised UK immune claim via the vitamin C content even if the beta-glucan content cannot make any claim of its own.
The PDP-honest position: the authorised claim attaches to the vitamin C, not to the mushroom or yeast extract. The encyclopaedia entry for the specific mushroom (shiitake / maitake / reishi etc.) carries the beta-glucan trial detail.
Evidence: Vitamin C's UK Article 13.1 immune claim (gb-nhc:vitamin_c) is established. Mushroom / yeast beta-glucan immune trial evidence is at biomarker level not clinical endpoint level. The combination itself is rarely the trial unit. [5]
Doses studied: 80-1000 mg/day vitamin C plus 100-500 mg/day standardised mushroom or yeast β-(1-3,1-6) glucan.
Akkermansia muciniphila (next-generation probiotic)
Limited evidenceGut-immune axis cluster — β-(1-3,1-4) oat / barley + Akkermansia mucus-layer support.
Oat / barley β-glucan provides cholesterol-maintenance UK Article 13.1 claim at ≥3 g/day + soluble-fibre prebiotic substrate that supports microbiome diversity; Akkermansia delivers specific mucus-layer / metabolic-marker mechanism. Mechanism-complementary on cardiovascular + gut-barrier axes.
Evidence: Mechanism complementary; combination not directly trialled.
Doses studied: ≥3 g/day oat / barley β-glucan + pasteurised Akkermansia 10⁹-10¹⁰ CFU/day.
Berberine
Limited evidenceCardiovascular cluster — berberine + oat β-glucan cholesterol-maintenance combination.
Berberine LDL-receptor up-regulation + AMPK; oat β-glucan bile-acid sequestration. Mechanism complementary on cholesterol axis.
Evidence: Camden beta-glucan UK Article 13.1 / Article 14 cholesterol claims.
Doses studied: 500-1500 mg berberine + ≥3 g/day oat β-glucan.
Chaga
Limited evidenceChaga β-(1-3,1-6) glucan + melanin polysaccharide complexes — Camden beta-glucan is the cluster molecular pillar.
Chaga has higher melanin content than other medicinal mushrooms — may contribute additional antioxidant signalling beyond standard β-glucan Dectin-1 mechanism.
Evidence: Camden beta-glucan covers cluster.
Doses studied: 300-1000 mg chaga extract daily.
Faecalibacterium prausnitzii (next-generation butyrate-producing probiotic)
Limited evidencePrebiotic fibre cluster — oat / barley β-glucan supports F. prausnitzii butyrate production.
F. prausnitzii ferments β-(1-3,1-4) glucan from oats / barley → butyrate. UK Article 13.1 / Article 14 oat β-glucan cholesterol claim is mechanistically supported by butyrate-producer microbiome modulation.
Evidence: Camden beta-glucan covers cluster.
Doses studied: ≥3 g/day oat / barley β-glucan (cholesterol-claim threshold) supports endogenous F. prausnitzii.
Kefir (Multi-strain fermented milk)
Limited evidenceYeast component of kefir contributes β-(1-3,1-6) glucan; pairs with oat / barley β-(1-3,1-4) glucan for cardiovascular cluster.
Kefir Saccharomyces yeasts have cell-wall β-(1-3,1-6) glucan content; oat / barley β-(1-3,1-4) glucan delivers UK Article 14 cholesterol-reduction and Article 13.1 maintenance claims at ≥3 g/day. Different glucan classes, mechanism-complementary on cardiovascular fibre + immune-modulation axes. Camden beta-glucan covers the molecular distinction.
Evidence: Mechanism complementary; combination not directly trialled.
Doses studied: Kefir 100-300 mL/day + ≥3 g/day oat / barley β-glucan for the cholesterol-claim threshold.
Maitake (Grifola frondosa)
Limited evidenceMaitake D-fraction is a canonical β-(1-3,1-6) glucan preparation — Camden beta-glucan is the molecular pillar.
D-fraction is the most-trialled maitake β-glucan isolate (Nanba 1997 onward). Mechanism: Dectin-1 / CR3 innate immune signalling.
Evidence: Camden beta-glucan covers cluster.
Doses studied: 300-1000 mg maitake D-fraction-standardised extract daily.
Roseburia intestinalis (next-generation butyrate-producing probiotic)
Limited evidencePrebiotic fibre — oat / barley β-glucan supports Roseburia butyrate production.
Roseburia ferments dietary β-glucan → butyrate via butyrate-kinase pathway. UK Article 13.1 / Article 14 oat β-glucan cholesterol claim mechanistically supported by butyrate-producer microbiome modulation.
Evidence: Camden beta-glucan covers cluster.
Doses studied: ≥3 g/day oat / barley β-glucan supports endogenous Roseburia.
Shiitake (Lentinula edodes)
Limited evidenceShiitake β-(1-3,1-6) glucan is the canonical Mycofera-cluster active. Camden beta-glucan is the molecular pillar.
Shiitake fruiting-body delivers β-(1-3,1-6) glucan via Dectin-1 receptor; oat / barley β-(1-3,1-4) glucan delivers cholesterol claim. Different glucan classes, different regulatory positions.
Evidence: Camden beta-glucan covers cluster.
Doses studied: 300-1000 mg shiitake extract + ≥3 g/day oat β-glucan for the cholesterol claim threshold.